Needham lowered the firm’s price target on Harmony Biosciences (HRMY) to $48 from $49 and keeps a Buy rating on the shares. Feedback from an expert call and positive pivotal data from Takeda (TAK) underscore that OX2R agonists will impact use of other daytime treatments like Harmony’s Wakix, the analyst tells investors in a research note. As such, Needham increased the rate of Wakix’s market share decline in narcolepsy type I.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences: Buy Rating Affirmed on Strong Growth Prospects and Strategic Advancements
- 3 Best Stocks to Buy Now, 8/6/2025, According to Top Analysts
- Harmony Biosciences Earnings Call Highlights Growth and Innovation
- Harmony Biosciences Holdings: Strong Patient Growth and Promising Pipeline Support Buy Rating
- Harmony Biosciences backs FY25 revenue view $820M-$860M, consensus $843.63M